Levamisole and Isoprinosine in the Treatment of COVID19: A Proposed Therapeutic Trial

The Efficacy of Levamisole and Isoprinosine in the Treatment of COVID19: A Proposed Therapeutic Trial

The use of both levamisole & Isoprinosine has both synergistic and complementary effect in the treatment of COVID 19 infection

Study design: Randomized controlled trial, randomization by closed envelope technique Informed consent will be written for each patient of either group At the beginning of the study all patients will have the following investigations done: CBC with differential, ESR, PCR for COVID 19, D dimer and CT chest and confirmed cases will included in the study Pregnant and lactating women together with children with other comorbidities will be excluded from the study Study groups: Duration of the study is 4 weeks Both groups with persistent COVID 19 symptoms that require hospitalization Group 1: 30 patients with confirmed COVID19 infection and sharing clinical features like fever, malaise, sore throat, runny nose, persistent cough &dyspnea, requiring hospitalization Group 2: control group: 30 patients Treatment endpoint • Cure of patients: Improvement of symptoms Laboratory findings ESR and total leucocytic count returning to normal PCR negative Radiological improvement • Worsening of symptoms or fatalities

oral tablets levamisole 50 mg 3 times daily every other day for 2 weeks Isoprinosine oral tablets 1 g 4 times daily for 2 weeks

Inclusion Criteria: Confirmed COVID 19 infection (positive PCR, elevated ESR, leucopenia) Clinical picture of COVID 19 infection including fever, malaise, sore throat, coughing, dyspnea, and runny nose Exclusion Criteria: Mild cases of COVID 19 that do not require hospitalization Pregnant & lactating women Children with other comorbidities People who received previous treatment for COVID 19 in the last 2 weeks N.B. Diabetes and hypertension not excluded